Completed PHASE1 INTERVENTIONAL 3-arm NCT00586222

Omega 3 Fatty Acid Trial

Neurometabolic Effects of the Essential Polyunsaturated Fatty Acids in Early-Onset Bipolar Disorder: A Magnetic Resonance Spectroscopy Study

Sponsor: Mayo Clinic

Conditions Adolescent Bipolar Disorder Magnetic Resonance Spectroscopy Imaging Omega-3 Fatty Acids Pediatric Bipolar Disorder

Interventions Omega-3 Fatty Acid Placebo

Updated 5 times since 2017 Last updated: Jan 24, 2012 Started: Jan 31, 2007 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Adolescent Bipolar Disorder and Magnetic Resonance Spectroscopy Imaging, this trial is completed. The trial is conducted by Mayo Clinic and has accumulated 5 data snapshots since 2007. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic
National Institutes of Health (NIH)

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States